CN102940133A - 多肽ca19在制备山羊饲料添加剂中的应用 - Google Patents
多肽ca19在制备山羊饲料添加剂中的应用 Download PDFInfo
- Publication number
- CN102940133A CN102940133A CN2012105352648A CN201210535264A CN102940133A CN 102940133 A CN102940133 A CN 102940133A CN 2012105352648 A CN2012105352648 A CN 2012105352648A CN 201210535264 A CN201210535264 A CN 201210535264A CN 102940133 A CN102940133 A CN 102940133A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- peptide
- application
- feed additives
- goat feed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
本发明涉及多肽CA19在制备山羊饲料添加剂中的应用，属于多肽技术领域。分子量为2069.45 Da,等电点为 9.16，氨基酸序列为AGGRCENGVC LCRKTNFKL的多肽CA19在制备山羊饲料添加剂的应用。本发明的效果在于：用多肽DM29制备的山羊饲料添加剂，抑菌效果明显。
Description
技术领域：
本发明涉及多肽CA19在制备山羊饲料添加剂中的应用，属于多肽技术领域。
背景技术：
抗生素的广泛应用,耐药菌株和多重耐药菌株日益增加,临床抗感染治疗已面临严峻挑战,寻找广谱高效的抗细菌、抗病毒药物,仍然是一个十分艰巨的任务。抗菌肽是动物体内极为重要的先天免疫物质，是一种具有高效抗菌、抗病毒、免疫功能的生物活性因子。抗菌肽是宿主非特异性免疫防御系统产生的一类对抗外源性病原体的肽类活性物质，是天然免疫的效应分子。研究表明，抗菌肽有着与传统抗生素完全不同的作用机制，不易诱导耐药菌株的产生；抗菌谱广，对细菌、真菌、病毒、原虫及癌细胞均有作用。在家禽上，已经发现了3个家族的抗菌肽包括cathelicidin, liver-expressed antimicrobial peptide (LEAP), and β-defensin。 这些抗菌肽对于家禽抵抗细菌性、病毒性疾病具有至关重要的作用。相关这些基因的突变或者缺失对于家禽抗微生物感染的能力将有显著的影响。这些些抗菌肽除了具有广谱抗菌活性，同时还有高效的抗真菌、抗病毒、抗原虫和（或）抗肿瘤活性，如Bat5和IMc7能杀灭钩端螺旋体，对白色念珠菌、隐球菌和包膜病毒和寄生虫都有较好的杀灭作用；一些抗菌肽对疱疹病毒、流感病毒、艾滋病病毒等有囊膜病毒有明显的杀伤力。此外，有些抗菌肽同时还具有多种其他的调控功能，如Cathelicidin还具有促进伤口愈合、组织损伤修复、化学趋化作用、促血管生成和抗寄生虫等功能，在调节动物机体免疫上有着重要生物学活性。
发明内容：
本发明的目的在于提供多肽CA19在制备山羊饲料添加剂中的应用。
本发明的所用的山羊饲料添加剂多肽CA19采用常规的化学合成的方法获得，多肽CA19的分子量为2069.45 Da,等电点为 9.16，氨基酸序列为AGGRCENGVC LCRKTNFKL。该多肽CA19在制备山羊饲料添加剂中的应用。
多肽CA19的抗菌试验，其试验方案为常规方法，具体如下：
将已制备好的高柱肉汤琼脂培养基加热熔化后,待冷却至50℃左右时,加入肉汤培养基菌液1mL(经过恒温37℃培养18小时的菌液),轻轻摇动,使之均匀.然后倒入无菌的平皿内,轻轻晃动平皿,以使培养基均匀地平铺在平皿上,待冷却凝固后,用消毒过的镊子将青霉素干纸片、链霉素干纸片、四环素干纸片、磺胺嘧啶干纸片整齐有顺序的放入平血内,盖上陶瓦盖,标好记号置37℃恒温培养箱内培养24小时.24小时后取出培养基,用卡尺量取抑菌圈大小并记录之,并比较不同抗菌药物对不同细菌的作用强度。
本发明的效果在于：用多肽DM29制备的山羊饲料添加剂，抑菌效果明显。
附图说明：
图1是山羊饲料添加剂多肽CA19对大肠杆菌的抑制效果。
具体实施方式：
下面结合附图对本发明作进一步的详细说明。
实施例所用的山羊饲料添加剂多肽CA19采用常规的化学合成的方法获得，山羊饲料添加剂多肽CA19的分子量为2069.45 Da,等电点为 9.16，氨基酸序列为AGGRCENGVC LCRKTNFKL。
多肽CA19的抗菌试验具体步骤同发明内容部分的描述。
实施例1 ：
多肽CA19对大肠杆菌的抑制作用。
取6μg/ml、以及10μg/ml山羊饲料添加剂多肽CA19进行抑菌试验。结果为：6ug/ml山羊饲料添加剂多肽CA19仅有较弱的抑菌效果（图1-B），10ug/ml山羊饲料添加剂多肽CA19抑菌效果很明显（图1-C）,图1-A为山羊饲料添加剂多肽CA19抑菌效果试验对照。
实施例2 ：
多肽CA19对不同微生物的最低抑菌浓度。
取不同浓度的山羊饲料添加剂多肽CA19分别抑制大肠杆菌、绿脓杆菌、金色葡萄球菌，枯草杆菌以及白色念珠菌。其中表1为该多肽对大肠杆菌、绿脓杆菌、金色葡萄球菌，枯草杆菌以及白色念珠菌的最低抑制浓度分别为：4.83μg/ml,13.85μg/ml, 18.39 μg/ml,1.42μg/ml, 32.04μg/ml。
表1
SEQUENCE LISTING
<110> 中国科学院昆明动物研究所
<120> 多肽CA19在制备山羊饲料添加剂中的应用
<130> 1
<160> 1
<170> PatentIn version 3.3
<210> 1
<211> 19
<212> PRT
<213> Capra ibex
<400> 1
Ala Gly Gly Arg Cys Glu Asn Gly Val Cys Leu Cys Arg Lys Thr Asn
1 5 10 15
Phe Lys Leu
Claims (1)
1.分子量为2069.45 Da,等电点为 9.16，氨基酸序列为AGGRCENGVCLCRKTNFKL的多肽CA19在制备山羊饲料添加剂中的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105352648A CN102940133B (zh) | 2012-12-12 | 2012-12-12 | 多肽ca19在制备山羊饲料添加剂中的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2012105352648A CN102940133B (zh) | 2012-12-12 | 2012-12-12 | 多肽ca19在制备山羊饲料添加剂中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102940133A true CN102940133A (zh) | 2013-02-27 |
| CN102940133B CN102940133B (zh) | 2013-08-14 |
Family
ID=47723217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2012105352648A Expired - Fee Related CN102940133B (zh) | 2012-12-12 | 2012-12-12 | 多肽ca19在制备山羊饲料添加剂中的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102940133B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0182278A2 (en) * | 1984-11-19 | 1986-05-28 | Wakunaga Seiyaku Kabushiki Kaisha | Antibacterial polypeptide, preparation thereof, and use thereof |
| CN101386640A (zh) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
-
2012
- 2012-12-12 CN CN2012105352648A patent/CN102940133B/zh not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0182278A2 (en) * | 1984-11-19 | 1986-05-28 | Wakunaga Seiyaku Kabushiki Kaisha | Antibacterial polypeptide, preparation thereof, and use thereof |
| CN101386640A (zh) * | 2008-09-27 | 2009-03-18 | 中国科学院昆明动物研究所 | 金环蛇抗菌肽cathelicidin-BF变异体cathelicidin-BF15及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102940133B (zh) | 2013-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hancock et al. | Antibiofilm activity of host defence peptides: Complexity provides opportunities | |
| Menousek et al. | Database screening and in vivo efficacy of antimicrobial peptides against methicillin-resistant Staphylococcus aureus USA300 | |
| Mohamed et al. | Targeting methicillin-resistant Staphylococcus aureus with short salt-resistant synthetic peptides | |
| Cherkasov et al. | Use of artificial intelligence in the design of small peptide antibiotics effective against a broad spectrum of highly antibiotic-resistant superbugs | |
| Estes et al. | Present and future therapeutic strategies for melioidosis and glanders | |
| ES2429108T3 (es) | Péptidos antibióticos | |
| JP7267251B2 (ja) | 抗菌組成物及び医薬組成物 | |
| Garcia et al. | Antimicrobial peptides from arachnid venoms and their microbicidal activity in the presence of commercial antibiotics | |
| KR100891157B1 (ko) | 짧은 생물활성 펩티드 및 그것들의 사용 방법 | |
| CN102702333B (zh) | 抗耐药性病原菌感染多肽及其用途 | |
| Kaur et al. | Design and molecular docking studies of novel antimicrobial peptides using autodock molecular docking software | |
| GB201018518D0 (en) | Novel endolysin | |
| de Freire Bastos et al. | Staphylococcins: an update on antimicrobial peptides produced by staphylococci and their diverse potential applications | |
| León-Sicairos et al. | Bactericidal effect of bovine lactoferrin and synthetic peptide lactoferrin chimera in Streptococcus pneumoniae and the decrease in lux S gene expression by lactoferrin | |
| Li et al. | An enhanced variant designed from DLP4 cationic peptide against Staphylococcus aureus CVCC 546 | |
| Memarpoor-Yazdi et al. | A novel antimicrobial peptide derived from the insect Paederus dermatitis | |
| Underwood et al. | Innate immunity and the role of defensins in otitis media | |
| Kang et al. | Effective antimicrobial activity of a peptide mutant Cbf-14-2 against penicillin-resistant bacteria based on its unnatural amino acids | |
| Wang et al. | Housefly Phormicin inhibits Staphylococcus aureus and MRSA by disrupting biofilm formation and altering gene expression in vitro and in vivo | |
| O'Neill et al. | Antimicrobials from a feline commensal bacterium inhibit skin infection by drug-resistant S. pseudintermedius | |
| Nguyen et al. | Avian antimicrobial peptides: in vitro and in ovo characterization and protection from early chick mortality caused by yolk sac infection | |
| Getahun et al. | Multidrug-resistant microbial therapy using antimicrobial peptides and the CRISPR/Cas9 system | |
| Rodrigues et al. | Adevonin, a novel synthetic antimicrobial peptide designed from the Adenanthera pavonina trypsin inhibitor (ApTI) sequence | |
| Gogoi et al. | Linear and branched forms of short antimicrobial peptide-IRK inhibit growth of multi drug resistant Staphylococcus aureus isolates from mastitic cow milk | |
| Wang et al. | Synergistic interaction of PMAP-36 and PRW4 with aminoglycoside antibiotics and their antibacterial mechanism |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130814 Termination date: 20131212 |